Other news to note
Wednesday, August 6, 2014
Genoa Pharmaceuticals Inc., of San Diego, said the FDA has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program, inhaled GP-101 for the treatment of idiopathic pulmonary fibrosis (IPF).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.